InMed is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.
See more at: https://www.edisongroup.com/our-content/